Outcome Notes
DISEASE PROGRESSION, DISEASE
The objective response rate was 10%, with 1 partial response and 9 patients with stable disease. There was a significantly improved time to disease progression, defined by PSA and/or radiographic progression, in responders as compared to non-responders (206 vs. 35 days, HR 0.26, 95% CI, 0.02-0.24, 